The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.

During the 17-year period 1972 through 1988, a total of seven cases of agranulocytosis associated with the use of dapsone for the treatment of dermatitis herpetiformis were reported in Sweden. The median age of the patients involved was 61 years; three of them were male. The median duration of dapsone treatment was 7 weeks and the daily prescribed dose was 100 mg. Based on sales and prescription data, the crude relative risk of agranulocytosis during dapsone treatment of dermatitis herpetiformis was 50, and the total risk was one case per 3000 patient years of exposure to dapsone. In relation to the number of new cases of dermatitis herpetiformis, agranulocytosis was estimated to develop in 1 of 240 to 425 patients receiving dapsone therapy. Patients should be instructed to seek medical care immediately in case of fever.

[1]  J. Palmblad,et al.  Drug-induced neutropenia--a survey for Stockholm 1973-1978. , 2009, Acta medica Scandinavica.

[2]  A. Ost,et al.  [Drug-induced agranulocytosis. A case control study]. , 1989, Lakartidningen.

[3]  H. Guess,et al.  Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data. , 1987, American journal of epidemiology.

[4]  T. Godal,et al.  Deficiency of cell mediated immunity in leprosy. , 1986, Progress in allergy.

[5]  R. Stockbrügger,et al.  Gastric morphology and function in dermatitis herpetiformis and in coeliac disease. , 1985, Scandinavian journal of gastroenterology.

[6]  L. Nilsson,et al.  Incidence and prevalence of dermatitis herpetiformis in western Sweden. , 1984, Acta dermato-venereologica.

[7]  L. Bruce-Chwatt,et al.  Agranulocytosis associated with Maloprim. , 1984, British medical journal.

[8]  J. Ginsburg,et al.  Climacteric flushing in a man. , 1983, British medical journal.

[9]  G. Friman,et al.  Agranulocytosis associated with malaria prophylaxis with Maloprim. , 1983, British medical journal.

[10]  F. Firkin,et al.  AGRANULOCYTOSIS DUE TO DAPSONE , 1977, The Medical journal of Australia.

[11]  W. Graham.  ADVERSE EFFECTS OF DAPSONE , 1975, International journal of dermatology.

[12]  B. Westerholm,et al.  Drug-induced Blood Dyscrasias in Sweden , 1973, British medical journal.

[13]  A. Ognibene.  Agranulocytosis due to dapsone. , 1970, Annals of internal medicine.

[14]  P. Levine,et al.  Pseudoleukemia during recovery from dapsone-induced agranulocytosis. , 1968, Annals of internal medicine.

[15]  A. Chalmers,et al.  Agranulocytosis Following Dapsone Therapy , 1958, British medical journal.

[16]  K Strandberg,et al.  Regulatory decisions. Emphasis on safety issues. , 1986, Medical toxicology.

[17]  L. Cunningham,et al.  Agranulocytosis during dapsone administration. , 1973, Dermatologica.

[18]  R. Hendrickse,et al.  The suppression of malarial parasitaemia by pyrimethamine in combination with dapsone or sulphormethoxine. , 1969, Transactions of the Royal Society of Tropical Medicine and Hygiene.